These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1498996)

  • 1. Serotonergic mechanisms of ECT: neuroendocrine evidence.
    Shapira B; Newman M; Lerer B
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():673A-674A. PubMed ID: 1498996
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression.
    Shapira B; Lerer B; Kindler S; Lichtenberg P; Gropp C; Cooper T; Calev A
    Br J Psychiatry; 1992 Feb; 160():223-9. PubMed ID: 1540763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine markers of serotonin responsivity in depression.
    Stahl SM
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Sep; 16(5):655-9. PubMed ID: 1496123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.
    Stahl SM; Hauger RL; Rausch JL; Fleishaker JC; Hubbell-Alberts E
    Clin Neuropharmacol; 1993; 16 Suppl 3():S19-31. PubMed ID: 8131152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment.
    O'Keane V; McLoughlin D; Dinan TG
    J Affect Disord; 1992 Nov; 26(3):143-50. PubMed ID: 1460163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ECT-induced PRL release: a 5-HT1A-mediated event?
    Zis AP; Goumeniouk AD; Clark CM; Remick RA; Adams SA
    Biol Psychiatry; 1992 Feb; 31(4):415-8. PubMed ID: 1558905
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking.
    Balldin J; Berggren U; Engel J; Eriksson M
    Alcohol Clin Exp Res; 1994 Aug; 18(4):822-5. PubMed ID: 7978090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.
    Lerer B; Ran A; Blacker M; Silver H; Weller MP; Drummer D; Ebstein B; Calev A
    Schizophr Res; 1988; 1(6):405-10. PubMed ID: 3154528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression.
    Siever LJ; Murphy DL; Slater S; de la Vega E; Lipper S
    Life Sci; 1984 Mar; 34(11):1029-39. PubMed ID: 6700367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of serotonin3 receptors in prolactin release induced by electroconvulsive therapy: a study with ondansetron.
    Yatham LN; Zis AP; Lam RW; Srisurapanont M; McGarvey K; Agbayewa O
    Psychiatry Res; 1996 Feb; 60(1):33-9. PubMed ID: 8852866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder.
    McBride PA; DeMeo MD; Sweeney JA; Halper J; Mann JJ; Shear MK
    Biol Psychiatry; 1992 Jan; 31(1):19-34. PubMed ID: 1311964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECT versus tricyclic antidepressants in depression: a review of the evidence.
    Rifkin A
    J Clin Psychiatry; 1988 Jan; 49(1):3-7. PubMed ID: 3275634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression.
    Cowen PJ; McCance SL; Cohen PR; Julier DL
    Psychopharmacology (Berl); 1989; 99(2):230-2. PubMed ID: 2508159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritanserin, a 5-HT2 receptor antagonist, does not modify ECT-induced prolactin release.
    Papakostas Y; Markianos M; Papadimitriou G; Stefanis C
    Psychopharmacology (Berl); 1990; 100(2):206-8. PubMed ID: 2106150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of relapse with tryptophan depletion following successful treatment with ECT.
    Cassidy F; Murry E; Weiner RD; Carroll BJ
    Am J Psychiatry; 1997 Aug; 154(8):1151-2. PubMed ID: 9247406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients.
    Shapira B; Reiss A; Kaiser N; Kindler S; Lerer B
    J Affect Disord; 1989; 16(1):1-4. PubMed ID: 2521644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action.
    Price LH; Charney DS; Delgado PL; Anderson GM; Heninger GR
    Arch Gen Psychiatry; 1989 Jul; 46(7):625-31. PubMed ID: 2500111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECT and antidepressants.
    Peterson GN
    J Clin Psychiatry; 1988 Nov; 49(11):455. PubMed ID: 3053670
    [No Abstract]   [Full Text] [Related]  

  • 19. Methysergide reduces the prolactin response to ECT.
    Papakostas Y; Markianos M; Stefanis C
    Biol Psychiatry; 1988 Aug; 24(4):465-8. PubMed ID: 3408764
    [No Abstract]   [Full Text] [Related]  

  • 20. Relapse and recurrence following a course of ECT: reasons for concern and strategies for further investigation.
    Grunhaus L; Dolberg O; Lustig M
    J Psychiatr Res; 1995; 29(3):165-72. PubMed ID: 7473293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.